Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.41 |
| ▸ | CALCR | P30988 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 8/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31218906 | 0.90 | GRB2 (0.51) | GRB2CAPN1RAMP3CALCRBDKRB2 | |
| SCHEMBL29546551 | 0.84 | GRB2 (0.48) | GRB2CAPN1CTSDBACE1CALCRL | |
| SCHEMBL29547288 | 0.84 | GRB2 (0.48) | GRB2CAPN1CTSDBACE1CALCRL | |
| SCHEMBL8054556 | 0.84 | GRB2 (0.47) | GRB2CAPN1CALCRL | |
| SCHEMBL8054560 | 0.84 | GRB2 (0.47) | GRB2CAPN1CALCRL | |
| SCHEMBL31064871 | 0.84 | CAPN1 (0.48) | GRB2CAPN1CALCRLCTSB | |
| SCHEMBL31696320 | 0.83 | CTSD (0.45) | GRB2CAPN1CTSDBACE1F2 | |
| SCHEMBL30444471 | 0.83 | CTSD (0.46) | GRB2CTSDBACE1CALCRLF2 | |
| SCHEMBL31126281 | 0.83 | CALCRL (0.43) | CAPN1CALCRLF2CXCL8 | |
| SCHEMBL30443935 | 0.83 | CALCRL (0.46) | GRB2CTSDBACE1CALCRLF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551565-B2 | CD44 targeted multi-arm conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| EP-3928797-B1 | CD44 TARGETED MULTI-ARM CONJUGATE | BRIGHTGENE BIO MEDICAL TECH CO LTD (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20220096644-A1 | CD44 TARGETED MULTI-ARM CONJUGATE | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551565-B2 | CD44 targeted multi-arm conjugate | CD44, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MUC1 | GRB2 3175/4885CAPN1 1266/4885CTSD 4077/4885 |
| US-20220096644-A1 | CD44 TARGETED MULTI-ARM CONJUGATE | CD44, BCL6, SIGLEC7 | GRB2 3145/4885CAPN1 2481/4885CTSD 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.